Nick Shillingford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nick Shillingford has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Mikako Warren
Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
5 shared publications - Andrew Goodspeed
University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado
4 shared publications - Christopher Kuo
Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA
4 shared publications - James F. Amatruda
Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Los Angeles, CA, USA
4 shared publications - Krinio Giannikou
Cancer Genetics Laboratory, Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States
4 shared publications - Masanori Hayashi
Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado
4 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e90930
Overseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean: Protocol for a Multicountry Mixed Methods Study (CaSIDEC Study)
Background: Small island developing states (SIDS) are home to approximately 65 million people worldwide. SIDS have some of the highest rates of cancer mortality burden in the developing world. Disparities in cancer mortality could be attributed to reliance on services overseas, which is a common feature across SIDS due to limited resources for comprehensive cancer care on the islands. However, overseas travel for cancer care remains largely understudied in SIDS, and epidemiological data on the implications on cancer survivorship are lacking. Objective: We aim primarily to map patterns of overseas travel for cancer care among cancer survivors in Caribbean SIDS and examine the lived experiences of cancer survivors and caregivers. Additionally, we will explore how overseas travel may affect key domains of cancer survivorship. Methods: We will conduct a multicountry, cross-sectional study using a convergent mixed methods design. We will establish a sample of 900 cancer survivors residing in the islands of Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent. Eligible participants will be adult cancer survivors who have accessed health services in their island of residence due to cancer. Sites for recruitment will be cancer support groups and hospitals. Surveys will be conducted face-to-face. For every country visited for diagnosis and/or treatment, we will record the services accessed and motives for the choice of country. We will compute the proportions of patients traveling for cancer care by country of destination. We will use regression models to explore associations with time to treatment and lifestyle factors (after treatment). In-depth interviews (n=24) and focus groups (n=54 participants) will be conducted with cancer survivors and caregivers to learn about overseas travel with an emphasis on social support systems. Open-ended questions and prompts will assess aspects of the day-to-day logistics and travel arrangements and experience living overseas. We will use an inductive thematic analysis approach to identify and interpret patterns. Results: Planning and development to implement the logistics for data collection were started in February 2023. We started with pilot testing in September 2024, and we have recruited 113 cancer survivors as of May 31 , 2026. We envisage active patient recruitment and data collection until March 31 , 2029, across all participating countries. Conclusions: This is the first multicountry study on overseas travel on cancer care in Caribbean SIDS. Our work will produce evidence that will inform recommendations to fill performance gaps in transnational systems for cancer care in the Eastern Caribbean that will improve patients’ lives. It is an important first step to developing data resources for high-quality research in understudied SIDS.
- 31 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e90930
Open AccessOverseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean: Protocol for a Multicountry Mixed Methods Study (CaSIDEC Study)
Background: Small island developing states (SIDS) are home to approximately 65 million people worldwide. SIDS have some of the highest rates of cancer mortality burden in the developing world. Disparities in cancer mortality could be attributed to reliance on services overseas, which is a common feature across SIDS due to limited resources for comprehensive cancer care on the islands. However, overseas travel for cancer care remains largely understudied in SIDS, and epidemiological data on the implications on cancer survivorship are lacking. Objective: We aim primarily to map patterns of overseas travel for cancer care among cancer survivors in Caribbean SIDS and examine the lived experiences of cancer survivors and caregivers. Additionally, we will explore how overseas travel may affect key domains of cancer survivorship. Methods: We will conduct a multicountry, cross-sectional study using a convergent mixed methods design. We will establish a sample of 900 cancer survivors residing in the islands of Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent. Eligible participants will be adult cancer survivors who have accessed health services in their island of residence due to cancer. Sites for recruitment will be cancer support groups and hospitals. Surveys will be conducted face-to-face. For every country visited for diagnosis and/or treatment, we will record the services accessed and motives for the choice of country. We will compute the proportions of patients traveling for cancer care by country of destination. We will use regression models to explore associations with time to treatment and lifestyle factors (after treatment). In-depth interviews (n=24) and focus groups (n=54 participants) will be conducted with cancer survivors and caregivers to learn about overseas travel with an emphasis on social support systems. Open-ended questions and prompts will assess aspects of the day-to-day logistics and travel arrangements and experience living overseas. We will use an inductive thematic analysis approach to identify and interpret patterns. Results: Planning and development to implement the logistics for data collection were started in February 2023. We started with pilot testing in September 2024, and we have recruited 113 cancer survivors as of May 31 , 2026. We envisage active patient recruitment and data collection until March 31 , 2029, across all participating countries. Conclusions: This is the first multicountry study on overseas travel on cancer care in Caribbean SIDS. Our work will produce evidence that will inform recommendations to fill performance gaps in transnational systems for cancer care in the Eastern Caribbean that will improve patients’ lives. It is an important first step to developing data resources for high-quality research in understudied SIDS.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Figures and Supplementary Table Legends
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Figures and Supplementary Table Legends
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose:The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma.Experimental Design:We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis.Results:We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism.Conclusions:In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose:The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma.Experimental Design:We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis.Results:We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism.Conclusions:In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- 23 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5051-5069
Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose: The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma. Experimental Design: We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis. Results: We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism. Conclusions: In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- 23 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5051-5069
Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose: The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma. Experimental Design: We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis. Results: We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism. Conclusions: In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- 20 May 2019
- Published by Wiley in Histopathology
- Vol. 75 (5) , 772-775
NTRK‐rearranged mesenchymal tumour in a 3‐year‐old female: a diagnostic quandary
- 20 May 2019
- Published by Wiley in Histopathology
- Vol. 75 (5) , 772-775
NTRK‐rearranged mesenchymal tumour in a 3‐year‐old female: a diagnostic quandary
- 14 May 2019
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 22 (3) , 252-257
Primary Epithelioid Sarcoma of the Zygomatic Bone
Primary epithelioid sarcoma (ES) of bone is extremely rare with only 2 reported cases in the English literature. A previously healthy 18-year-old man presented with a 6-month history of right facial numbness and tingling and right eye diplopia. A computerized tomography scan revealed an ill-defined mass with dense osseous matrix centered in the right zygomatic bone. An outside biopsy was read as osteosarcoma. The resection specimen revealed large epithelioid and spindle cells embedded in a prominent hyalinized matrix with focal metaplastic bone formation. The tumor cells were strongly and diffusely positive for AE1/AE3 and epithelial membrane antigen, but a definitive diagnosis of ES was not immediately reached due to the presence of dense hyalinized matrix and weak expression of SAT2B by tumor cells. Deficient INI1 protein expression by immunohistochemistry and homozygous loss of the SMARCB1 gene by chromosomal microarray analysis ultimately justified this tumor’s designation as ES.
- 14 May 2019
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 22 (3) , 252-257
Primary Epithelioid Sarcoma of the Zygomatic Bone
Primary epithelioid sarcoma (ES) of bone is extremely rare with only 2 reported cases in the English literature. A previously healthy 18-year-old man presented with a 6-month history of right facial numbness and tingling and right eye diplopia. A computerized tomography scan revealed an ill-defined mass with dense osseous matrix centered in the right zygomatic bone. An outside biopsy was read as osteosarcoma. The resection specimen revealed large epithelioid and spindle cells embedded in a prominent hyalinized matrix with focal metaplastic bone formation. The tumor cells were strongly and diffusely positive for AE1/AE3 and epithelial membrane antigen, but a definitive diagnosis of ES was not immediately reached due to the presence of dense hyalinized matrix and weak expression of SAT2B by tumor cells. Deficient INI1 protein expression by immunohistochemistry and homozygous loss of the SMARCB1 gene by chromosomal microarray analysis ultimately justified this tumor’s designation as ES.
- 11 May 2017
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 21 (5) , 480-485
Bronchial Mucoepidermoid Carcinoma With the Classic MAML2 Gene Rearrangement in a 2-year-old Boy
Pulmonary mucoepidermoid carcinoma (PMEC) is rare. To date, primary PMEC has not been reported in a child younger than 3 years of age. We report a case of a 2-year-old boy who presented with 3 episodes of wheezing, cough, and fever over a period of 1 month. Radiologic findings were consistent with foreign body aspiration with consequent bronchial obstruction. Bronchoscopy was performed and attempts to retrieve the foreign body resulted in a biopsy of a fleshy lesion. By histology, the lesion was an epithelial neoplasm comprising cells arranged in a nested pattern. The neoplastic cells were round with round nuclei and amphophilic, vacuolated cytoplasm. Our diagnosis was low-grade salivary gland-type carcinoma of the bronchus. The pneumonectomy specimen showed a well-circumscribed, polypoid intrabronchial mass measuring 2.1 cm in greatest dimension. Histologic examination of the tumor showed an admixture of intermediate cells which were predominant, a small number of mucus cells and rare foci of squamous cells. The final diagnosis rendered was a low-grade mucoepidermoid carcinoma of the bronchus. Accurate diagnosis of PMEC can be challenging on limited biopsy material as seen in the case reported here. The use of molecular studies such as MAML2 gene rearrangement may facilitate diagnosis in difficult cases. Increased awareness of this entity and further molecular studies are needed for a better understanding of the pathogenesis of PMEC. To date, the reported age range for primary bronchial mucoepidermoid carcinoma is between 3 years and 78 years. This case represents the youngest patient reported in the English literature.
- 11 May 2017
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 21 (5) , 480-485
Bronchial Mucoepidermoid Carcinoma With the Classic MAML2 Gene Rearrangement in a 2-year-old Boy
Pulmonary mucoepidermoid carcinoma (PMEC) is rare. To date, primary PMEC has not been reported in a child younger than 3 years of age. We report a case of a 2-year-old boy who presented with 3 episodes of wheezing, cough, and fever over a period of 1 month. Radiologic findings were consistent with foreign body aspiration with consequent bronchial obstruction. Bronchoscopy was performed and attempts to retrieve the foreign body resulted in a biopsy of a fleshy lesion. By histology, the lesion was an epithelial neoplasm comprising cells arranged in a nested pattern. The neoplastic cells were round with round nuclei and amphophilic, vacuolated cytoplasm. Our diagnosis was low-grade salivary gland-type carcinoma of the bronchus. The pneumonectomy specimen showed a well-circumscribed, polypoid intrabronchial mass measuring 2.1 cm in greatest dimension. Histologic examination of the tumor showed an admixture of intermediate cells which were predominant, a small number of mucus cells and rare foci of squamous cells. The final diagnosis rendered was a low-grade mucoepidermoid carcinoma of the bronchus. Accurate diagnosis of PMEC can be challenging on limited biopsy material as seen in the case reported here. The use of molecular studies such as MAML2 gene rearrangement may facilitate diagnosis in difficult cases. Increased awareness of this entity and further molecular studies are needed for a better understanding of the pathogenesis of PMEC. To date, the reported age range for primary bronchial mucoepidermoid carcinoma is between 3 years and 78 years. This case represents the youngest patient reported in the English literature.
- 1 April 2017
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 64 (4) , 512-517
Hepatic Inflammation May Influence Liver Stiffness Measurements by Transient Elastography in Children and Young Adults
Objectives: Transient elastography (TE) measures liver stiffness to assess fibrosis. Studies in adults have shown that inflammation increases stiffness, leading to an overestimation of fibrosis. We investigated the contribution of inflammation to liver stiffness measurements (LSMs) in children/young adults.Methods: This was a cohort analysis of children/young adults who underwent TE within 1 year of liver biopsy. Alanine aminotransferase (ALT) was obtained within 30 days of the biopsy and LSM. Fibrosis was assessed by METAVIR stage and inflammation by ALT and Ishak score. Data were stratified into METAVIR F0–F2 versus F3–F4. Change between ALT and LSM over time was also assessed.Results: A total of 154 patients (50% male patients) ages 3 weeks to 24 years (18% 8.6 kPa increased with increasing ALT (P = 0.002). In patients with F3–F4, there was no association between ALT and LSM (P = 0.17). A correlation between change in ALT and LSM was observed in patients with no/minimal fibrosis and inflammatory liver diseases (r = 0.33).Conclusions: In children with no/minimal hepatic fibrosis and inflammatory liver disease, high ALT values are associated with LSM in the range typical of advanced fibrosis. However, with more advanced fibrosis, inflammation does not appear to contribute to LSM. Caution must be taken when interpreting LSM for assessing fibrosis severity in the setting of inflammation.
- 1 April 2017
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 64 (4) , 512-517
Hepatic Inflammation May Influence Liver Stiffness Measurements by Transient Elastography in Children and Young Adults
Objectives: Transient elastography (TE) measures liver stiffness to assess fibrosis. Studies in adults have shown that inflammation increases stiffness, leading to an overestimation of fibrosis. We investigated the contribution of inflammation to liver stiffness measurements (LSMs) in children/young adults.Methods: This was a cohort analysis of children/young adults who underwent TE within 1 year of liver biopsy. Alanine aminotransferase (ALT) was obtained within 30 days of the biopsy and LSM. Fibrosis was assessed by METAVIR stage and inflammation by ALT and Ishak score. Data were stratified into METAVIR F0–F2 versus F3–F4. Change between ALT and LSM over time was also assessed.Results: A total of 154 patients (50% male patients) ages 3 weeks to 24 years (18% 8.6 kPa increased with increasing ALT (P = 0.002). In patients with F3–F4, there was no association between ALT and LSM (P = 0.17). A correlation between change in ALT and LSM was observed in patients with no/minimal fibrosis and inflammatory liver diseases (r = 0.33).Conclusions: In children with no/minimal hepatic fibrosis and inflammatory liver disease, high ALT values are associated with LSM in the range typical of advanced fibrosis. However, with more advanced fibrosis, inflammation does not appear to contribute to LSM. Caution must be taken when interpreting LSM for assessing fibrosis severity in the setting of inflammation.